LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Compugen Ltd

Gesloten

1.42 -1.39

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.42

Max

1.43

Belangrijke statistieken

By Trading Economics

Inkomsten

-161K

-7.3M

Verkoop

-1M

1.3M

K/W

Sectorgemiddelde

60.333

34.427

Winstmarge

-584.089

Werknemers

74

EBITDA

1M

-7.4M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+293.71% upside

Dividenden

By Dow Jones

Volgende Winsten

11 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.4M

140M

Vorige openingsprijs

2.81

Vorige sluitingsprijs

1.42

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Compugen Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 aug 2025, 16:11 UTC

Belangrijke Marktbewegers

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15 aug 2025, 22:22 UTC

Marktinformatie

Global Equities Roundup: Market Talk

15 aug 2025, 22:22 UTC

Marktinformatie

Target Is Falling Behind Its Peers -- Market Talk

15 aug 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 aug 2025, 20:33 UTC

Marktinformatie

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15 aug 2025, 20:25 UTC

Winsten
Acquisities, Fusies, Overnames

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15 aug 2025, 20:24 UTC

Winsten
Acquisities, Fusies, Overnames

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 aug 2025, 20:18 UTC

Winsten

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 aug 2025, 19:14 UTC

Marktinformatie

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15 aug 2025, 19:12 UTC

Marktinformatie

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15 aug 2025, 18:32 UTC

Marktinformatie

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15 aug 2025, 17:33 UTC

Marktinformatie

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15 aug 2025, 17:23 UTC

Marktinformatie
Winsten

Deere's Earnings Appear to Be Troughing -- Market Talk

15 aug 2025, 16:27 UTC

Winsten

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15 aug 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 aug 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

15 aug 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

15 aug 2025, 16:05 UTC

Acquisities, Fusies, Overnames

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15 aug 2025, 15:52 UTC

Acquisities, Fusies, Overnames

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15 aug 2025, 15:36 UTC

Marktinformatie

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15 aug 2025, 15:29 UTC

Winsten

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 aug 2025, 15:29 UTC

Acquisities, Fusies, Overnames

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 aug 2025, 15:28 UTC

Winsten

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15 aug 2025, 15:24 UTC

Marktinformatie

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15 aug 2025, 15:08 UTC

Marktinformatie

Applied Materials Is Losing Share in Chips Business -- Market Talk

15 aug 2025, 14:38 UTC

Acquisities, Fusies, Overnames

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15 aug 2025, 14:37 UTC

Acquisities, Fusies, Overnames

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15 aug 2025, 14:37 UTC

Acquisities, Fusies, Overnames

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15 aug 2025, 14:36 UTC

Acquisities, Fusies, Overnames

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15 aug 2025, 14:33 UTC

Acquisities, Fusies, Overnames

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Peer Vergelijking

Prijswijziging

Compugen Ltd Prognose

Koersdoel

By TipRanks

293.71% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.63 USD  293.71%

Hoogste 13 USD

Laagste 1.5 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Compugen Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Technische score

By Trading Central

1.25 / 1.48Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.